Chang Yue Chui1,2, Dennis Thomas1, Simone Taylor3, Billie Bonevski4, Michael J Abramson5, Eldho Paul5,6, Susan G Poole1,7, Gregory R Weeks1,8, Michael J Dooley1,7, Johnson George1. 1. Centre for Medicine Use and Safety, Monash University, Melbourne, Australia. 2. Department of Pharmaceutical Sciences, University of Utrecht, Utrecht, The Netherlands. 3. Pharmacy Department, Austin Health, Melbourne, Australia. 4. School of Medicine and Public Health, University of Newcastle, Newcastle, Australia. 5. School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. 6. Clinical Haematology Department, The Alfred, Melbourne, Australia. 7. Pharmacy Department, Alfred Health, Melbourne, Australia. 8. Pharmacy Department, Barwon Health, Geelong, Australia.
Abstract
INTRODUCTION AND AIMS: Nicotine replacement therapy (NRT) is recommended as a smoking cessation aid for hospitalised smokers. We examined factors associated with NRT use during hospitalisation and after discharge, and NRT uptake when systematically offered free of cost. DESIGN AND METHODS: A nested analysis was conducted using data from a clinical trial that evaluated the effectiveness of a pharmacist-led smoking cessation intervention in 600 hospitalised smokers. RESULTS:NRT was used at least once by 285 (48%) participants during hospitalisation and by 287 (48%) participants during the 12 months post-discharge. Heavy smokers and those who expressed interest in using NRT for their next quit attempt at baseline interview were more likely to use NRT during hospitalisation [odds ratio (OR) 1.94, 95% confidence interval (CI) 1.38, 2.74; OR 2.09, 95% CI 1.48, 2.95] and after discharge (OR 1.70, 95% CI 1.20, 2.41; OR 1.97, 95% CI 1.39, 2.79). Those using six or more medications were more likely to use NRT during hospitalisation (OR 1.65, 95% CI 1.05, 2.61). Post-discharge NRT users were more likely to have been initially admitted for a respiratory or cardiac problem (OR 1.51, 95% CI 1.05, 2.18). When NRT was offered free of cost to a subset of patients (n = 300), 157 (52%) used NRT during hospitalisation. Nicotine dependence and interest in using NRT predicted its use (OR 2.26, 95% CI 1.38, 3.70; OR 2.58, 95% CI 1.58, 4.20). DISCUSSION AND CONCLUSIONS: Targeting heavy smokers, those with cardio-respiratory conditions and those interested in using NRT regardless of regimen complexity could improve NRT uptake.
RCT Entities:
INTRODUCTION AND AIMS: Nicotine replacement therapy (NRT) is recommended as a smoking cessation aid for hospitalised smokers. We examined factors associated with NRT use during hospitalisation and after discharge, and NRT uptake when systematically offered free of cost. DESIGN AND METHODS: A nested analysis was conducted using data from a clinical trial that evaluated the effectiveness of a pharmacist-led smoking cessation intervention in 600 hospitalised smokers. RESULTS: NRT was used at least once by 285 (48%) participants during hospitalisation and by 287 (48%) participants during the 12 months post-discharge. Heavy smokers and those who expressed interest in using NRT for their next quit attempt at baseline interview were more likely to use NRT during hospitalisation [odds ratio (OR) 1.94, 95% confidence interval (CI) 1.38, 2.74; OR 2.09, 95% CI 1.48, 2.95] and after discharge (OR 1.70, 95% CI 1.20, 2.41; OR 1.97, 95% CI 1.39, 2.79). Those using six or more medications were more likely to use NRT during hospitalisation (OR 1.65, 95% CI 1.05, 2.61). Post-discharge NRT users were more likely to have been initially admitted for a respiratory or cardiac problem (OR 1.51, 95% CI 1.05, 2.18). When NRT was offered free of cost to a subset of patients (n = 300), 157 (52%) used NRT during hospitalisation. Nicotine dependence and interest in using NRT predicted its use (OR 2.26, 95% CI 1.38, 3.70; OR 2.58, 95% CI 1.58, 4.20). DISCUSSION AND CONCLUSIONS: Targeting heavy smokers, those with cardio-respiratory conditions and those interested in using NRT regardless of regimen complexity could improve NRT uptake.
Authors: Philip J Trapskin; Ann Sheehy; Paul D Creswell; Danielle E McCarthy; Amy Skora; Rob T Adsit; Anne E Rose; Candace Bishop; Jessica Bugg; Emily Iglar; Mark E Zehner; Daniel Shirley; Brian S Williams; Adam J Hood; Krista McElray; Timothy B Baker; Michael C Fiore Journal: Hosp Pharm Date: 2021-03-05
Authors: Paul D Creswell; Danielle E McCarthy; Philip Trapskin; Ann Sheehy; Amy Skora; Robert T Adsit; Mark E Zehner; Timothy B Baker; Michael C Fiore Journal: Am J Health Syst Pharm Date: 2022-06-07 Impact factor: 2.980
Authors: E Melinda Mahabee-Gittens; Ashley L Merianos; Meredith E Tabangin; Lara Stone; Judith S Gordon; Jane C Khoury Journal: Tob Prev Cessat Date: 2020-05-18